Navigation Links
Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients

ection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

COPAXONE(R) is now approved in 47 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In Europe, COPAXONE(R) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. In North America, COPAXONE(R) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA). COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

See additional important information at http://www.copaxone.com/pi/index.html or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
2. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
3. Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective
4. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
5. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
6. Point of Care Strep Tests Speed Treatment, Lower Costs
7. Rapid HIV Testing Increases Possibility of Treatment
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:8/29/2015)... ANDOVER, Massachusetts y LONDRES, August 29, 2015 ... Inteligencia Anatómica para los sistemas ... reproducibles en Ecografía, tiempos de examen rápidos ... se traduce en mayor confianza diagnóstica en el proceso ... Philips  (NYSE: PHG, AEX: PHIA) ha anunciado hoy el ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Pranoprofen Market, ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma Corporation ... an inflammatory drug, pranoprofen was later developed into ... the trade name of pranopulin for the treatment ...
(Date:8/28/2015)... , Aug. 28, 2015 Patterson ... Inc. (Nasdaq: PDCO ), is now an ... announced acquisition of Patterson Medical by Madison Dearborn ... retain its name for a transition period before ... rehabilitation and sports medicine products.  With the focused ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Investigation Report on China's Pranoprofen Market, 2010-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... April 3, 2011 Regado Biosciences, Inc., a privately ... active control agents, announced today the primary results of ... lead product, the anticoagulation system REG1, at the i2 ... Annual Scientific Session & Expo in New Orleans, LA. ...
... of the SPIRIT II, III, IV and COMPARE trials presented ... ABT ) market-leading XIENCE V ® Everolimus ... all four trials, two-year results on the safety and efficacy ... and TAXUS ® Express2™ Paclitaxel-Eluting Coronary Stent Systems ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 2Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 3Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 4Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 5Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 2Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 3Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 4
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( http://www.nutricompany.com ... of global cosmeceutical and skin care brands. Mr. Fernandez comes with a ... years working in operations, purchasing and management for some of the nations biggest ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at ... Community Colleges , will be hosting a Job Expo to provide a professional, open ... The Expo has expanded to much more than just a typical job and career ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... Ill., Jan. 30 SpineMark Corporation,a spinal care ... develop Spine Centers of Excellence, has entered into ... spinal care at,cost effective rates through the first ... the Healthplace Surgery Benefit(TM). As a result,of ...
... Snyder, president of Catholic Charities USA, issued the ... the State Children,s Health Insurance Program (SCHIP), a ... that do not qualify for Medicaid. The House ... on a compromise version of the legislation, which ...
... Jan. 30 Wellesse, manufacturers of new Liquid ... challenges participants to assess their vitamin knowledge for ... a personal nutrition consultation and a year,s supply ... research on Vitamin D dominates the headlines lately, ...
... for menopausal symptoms, FDA says , , FRIDAY, Jan. ... hormones or "bio-identical hormone replacement therapy," and they ... lose weight to preventing senility. , They,re touted ... conventional hormone-replacement therapy. , But the U.S. Food ...
... Co., Inc. (NYSE Alternext: TPI), a manufacturer and ... Chengdu, China,today announced that the Company has begun ... stock repurchase program. These shares will be,retired to ... shares of its,common stock. , ...
... exclusivity on the 500 mg strengthPITTSBURGH, Jan. 30 ... that its subsidiary Mylan Pharmaceuticals Inc. has received final ... for its Abbreviated New Drug Application (ANDA) for Divalproex ... mg. Mylan has been awarded 180 days of marketing ...
Cached Medicine News:Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4Health News:Catholic Charities USA Praises Congress for Protecting Health Care for Low-income Children 2Health News:Test Your Vitamin D Knowledge: Wellesse Liquid Sunshine Instant Win and Sweepstakes 2Health News:The Truth About 'Bio-identical' Hormone Therapy 2Health News:The Truth About 'Bio-identical' Hormone Therapy 3Health News:The Truth About 'Bio-identical' Hormone Therapy 4Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 2Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: